WASHINGTON DC (May 24, 2021) – Today Steven Selde is joining the Association for Accessible Medicines (AAM) as Director of the Biosimilars Council. This division of AAM educates the public and patients about the safety and effectiveness of biosimilars, focusing on access, the regulatory environment, reimbursement and legal affairs. Member organizations include manufacturers and stakeholders working to develop biosimilar products for the U.S. market. As Director, Steven will work with leadership to identify issues affecting Biosimilars Council members’ interests and develop and implement advocacy strategies and tactics that effectively support those interests.
Prior to joining AAM, Steven was Assistant Director, Government Affairs, for the Ambulatory Surgery Center Association (ASCA). In this role he represented ambulatory surgery centers before Congress and federal agencies. Prior to his work with ASCA, he served as legislative counsel for Senator Deb Fischer (R., Neb.); there, he was responsible for developing and progressing the senator’s policy positions on health care, education, labor, Veterans Affairs and Indian Affairs. Steven developed and executed strategies to enact Senator Fischer’s legislation, including the Communities Helping Invest through Property and Improvements Needed for Veterans Act (H.R.5099/S.3364), Strong Families Act (S.1716) and Veterans Fair Debt Notice Act (S.2248), all signed into law.
Steven attended Creighton University School of Law and received his BA from Fordham University.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.